首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Synthesis and Antifungal Activity In Vitro of Isoniazid Derivatives against Histoplasma capsulatum var. capsulatum
【2h】

Synthesis and Antifungal Activity In Vitro of Isoniazid Derivatives against Histoplasma capsulatum var. capsulatum

机译:异烟肼衍生物对荚膜组织胞浆菌的合成及其体外抑菌活性。荚膜

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Histoplasmosis is a severe infection that affects millions of patients worldwide and is endemic in the Americas. Amphotericin B (AMB) and itraconazole are highly effective for the treatment of severe and milder forms of the disease, but AMB is toxic, and the bioavailability of itraconazole is erratic. Therefore, it is important to investigate new classes of drugs for histoplasmosis treatment. In this study, a series of nine isoniazid hydrazone derivatives were synthesized and evaluated for their antifungal activities in vitro against the dimorphic fungus Histoplasma capsulatum var. capsulatum. The drugs were tested by microdilution in accordance with CLSI guidelines. The compound N′-(1-phenylethylidene)isonicotinohydrazide had the lowest MIC range of all the compounds for the yeast and filamentous forms of H. capsulatum. The in vitro synergy of this compound with AMB against the planktonic and biofilm forms of H. capsulatum cells was assessed by the checkerboard method. The effects of this hydrazone on cellular ergosterol content and membrane integrity were also investigated. The study showed that the compound alone is able to reduce the ergosterol content of planktonic cells and can alter the membrane permeability of the fungus. Furthermore, the compound alone or in combination with AMB showed inhibitory effects against mature biofilms of H. capsulatum. N′-(1-Phenylethylidene)isonicotinohydrazide alone or combined with AMB might be of interest in the management of histoplasmosis.
机译:组织胞浆菌病是一种严重的感染,影响全世界数以百万计的患者,并且在美洲流行。两性霉素B(AMB)和伊曲康唑对重度和轻度疾病的治疗非常有效,但AMB具有毒性,伊曲康唑的生物利用度不稳定。因此,研究用于治疗组织胞浆菌病的新型药物很重要。在这项研究中,合成了九个异烟肼系列衍生物,并评估了其对双形真菌荚膜组织胞浆变种的体外抗真菌活性。荚膜。根据CLSI指南,通过微量稀释对药物进行了测试。化合物N'-(1-苯基亚乙基)异烟酰肼具有用于酵母和荚膜H.丝状形式的所有化合物的最低MIC范围。通过棋盘法评估了该化合物与AMB在体外对荚膜梭菌浮游和生物膜形式的协同作用。还研究了该对细胞麦角固醇含量和膜完整性的影响。研究表明,单独使用该化合物可以降低浮游细胞中麦角固醇的含量,并可以改变真菌的膜通透性。此外,该化合物单独或与AMB结合显示出对荚膜嗜血杆菌成熟生物膜的抑制作用。单独或与AMB结合使用的N'-(1-苯乙叉基)异烟酰肼可能对组织胞浆菌病的治疗很感兴趣。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号